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performance score <40, suspected tuberculous meningitis, ≥ 1 week of antituberculosis 9 9 treatment, <3 months of antiretroviral therapy (ART), or use of a fluoroquinolone within the 1 0 0 past 8 weeks. Additional study details can be obtained from published reports [22, 33] . at the baseline visit, before CRP results were available. Sputum and urine specimens for 1 0 8 mycobacterial culture were obtained at the baseline visit. Participants' symptoms were 1 0 9 recorded, and functional status estimated using the Karnofsky Performance Score (KPS). Weight was measured in kilograms on a calibrated electronic scale, and C-reactive protein 1 1 1 (CRP) and haemoglobin were measured in venous blood at a commercial laboratory. Standardized clinical review was conducted in all participants at 2, 4 and 8 weeks after the 1 1 5 baseline visit, which included KPS, measurement of weight, CRP, and haemoglobin 1 1 6 concentration. A Symptom Score Ratio (SSR) was calculated by dividing the aggregate 1 1 7 number of symptoms reported as either markedly improved or resolved by the total number 1 1 8 of symptoms reported at baseline. Participants who deteriorated clinically were referred for deterioration occurred. These participants (re-baselined group) were then followed up on 1 2 3 treatment for a further 8 weeks and on-treatment data were included in the treatment group. Participants who missed a scheduled appointment were contacted telephonically and 1 2 6 rescheduled; these participants' data were included in the analysis if their visit was within 7 1 2 7 days of their scheduled visit for week 2, and 14 days for weeks 4 and 8. Participants were 1 2 8 offered HIV testing at each visit and those with a positive test were referred for antiretroviral 1 2 9 therapy at the week 8 visit in keeping with national policy at the time of the study. An adverse clinical event was defined as death or hospitalization for a medical condition. data points were excluded from the model. Data obtained from participants classified with an 1 4 7 7 adverse outcome after week 2 were retained in the analysis. Change in CRP was calculated 1 4 8 by subtracting the week 2 or week 8 value from the baseline value, and percentage change by 1 4 9 dividing the change by the baseline value. Change in haemoglobin concentration or weight 1 5 0 was calculated by subtracting the baseline measurement from the week 2 or week 8 1 5 1 measurement and dividing the change by the baseline value. Sensitivity / specificity decision 1 5 2 tables were generated and used to select CRP percentage change cut-offs with a sensitivity of The study was approved by ethics review boards of the Universities of KwaZulu-Natal and taking antiretroviral therapy at the baseline visit. Sixteen participants initially included in the 1 6 7 observation arm were diagnosed with tuberculosis and were started on antituberculosis diagnosis. CRP showed the greatest changes from baseline and the greatest early change in 1 7 7 the on-treatment tuberculosis groups. Only the objectively measured response to therapy follow up period in the group not treated for tuberculosis. In the group not treated for tuberculosis, the median CRP change did not change 1 9 1 1 9 8 confirmed and possible tuberculosis groups, but the magnitude of change was modest, and 1 9 9 changes at week 2 were not significant. At week 8, weight increased by 2.3% (IQR -1.0; 5.6) 2 0 0 in the entire group treated for tuberculosis, by 3.6% (IQR -0.7; 7.2) in the group with The subjectively assessed KPS and SSR parameters improved both in the tuberculosis group, Adverse outcomes in the group treated for tuberculosis were defined as either death (n=7) or 2 2 0 hospitalization (n=7) during the study period (Fig. 1) . At week 2, both CRP and the SSR 1 0 improvement was associated with death or hospitalization (Table 3) The median CRP reduction from baseline to week 2 was 31.0 mg/L (IQR 3.3; 77.1) in the and −6.0 mg/L (IQR −56.5; 1.0) in the 14 who died or were hospitalized (−33.8% reduction −198.8; 4.3] , (p-value <0.0001 for both comparisons). For the SSR, the median score 2 3 1 was 0.8 (IQR 0.63; 1.0) in the participants with an uncomplicated course, and 0.5 (IQR 0.21; 2 3 2 0.62) in those with an adverse outcome (p-value 0.001). Receiver operating characteristics for the combined endpoint of death or hospitalization vs. 
